Home Cart Sign in  
Chemical Structure| 502887-71-0 Chemical Structure| 502887-71-0

Structure of MMP-9-IN-1
CAS No.: 502887-71-0

Chemical Structure| 502887-71-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor that selectively targets the hemopexin (PEX) domain of MMP-9.

Synonyms: OUN87710

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MMP-9-IN-1

CAS No. :502887-71-0
Formula : C16H17F2N3O3S
M.W : 369.39
SMILES Code : O=C(NC1=CC=C(OC(F)F)C=C1)CSC2=NC(CCC)=CC(N2)=O
Synonyms :
OUN87710
MDL No. :MFCD09276885
InChI Key :OLTRRVUORWPRGF-UHFFFAOYSA-N
Pubchem ID :135415473

Safety of MMP-9-IN-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow mesenchymal stem cells (BMSC) 10 µM 1 week To evaluate the effect of MMP-9-IN-1 on CS expression and citric acid synthesis in BMSCs, results showed that MMP-9-IN-1 significantly increased the amount of CS in BMSCs and promoted cellular citric acid synthesis. PMC10866869
Bone marrow mesenchymal stem cells (BMSC) 0.1-1-10-100 µM 24, 48, 72 hours To evaluate the effect of MMP-9-IN-1 on CS expression and citric acid synthesis in BMSCs, results showed that MMP-9-IN-1 significantly increased the amount of CS in BMSCs and promoted cellular citric acid synthesis. PMC10866869
MDA-MB-231 cells 10 µM Inhibits PI4KIIα activity, reduces exosome secretion PMC11165029

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c-nu/nu immunocompromised mice Lung metastasis model Tail vein injection 0.5 g/kg Single injection, evaluated after 31 days Evaluate the inhibitory effect of TXA on lung metastasis PMC11002074
C57BL6/J mice Ovariectomy model (OVX) Intraperitoneal injection 2 mg/kg Twice a week, for 8 weeks To evaluate the effect of MMP-9-IN-1 on bone health in ovariectomized mice, results showed that MMP-9-IN-1 could improve bone mineral density (BMD), bone volume/tissue volume (BV/TV), trabecular number (Tb.N) and trabecular thickness (Tb.Th), and reduce trabecular separation (Tb.Sp). PMC10866869
C57BL/6 mice Acute myocardial infarction model Subcutaneous injection 10 μg/d Continued for 3 or 7 days MMP-9 inhibitor treatment attenuated the deteriorated effect of monoclonal anti-proBDNF antibody on cardiac function and infarct areas. PMC10111532

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.54mL

2.71mL

1.35mL

27.07mL

5.41mL

2.71mL

References

 

Historical Records

Categories